Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIFECTA-SCC: Triplet Immunotherapy for Advanced Squamous Cell Carcinoma
NCT07896811Phase 2Not yet recruiting
- Sponsor
- Medical College of Wisconsin
- Start
- Feb 2027
- Primary completion
- Aug 2029
- Countries
- 1
01
Overview
A Phase 2 trial of vilastobart in squamous cell carcinoma (SCC), sponsored by Medical College of Wisconsin. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
vilastobart
03
Conditions
squamous cell carcinoma (SCC)
Beyond the preview
Go deeper on NCT07896811.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07896811.